The global Canine cancer market size was estimated at USD 199.9 million in 2019 and is anticipated to witness a CAGR of 10.7% during the forecast period. The increasing pervasiveness of cancer in the pet population and rising adoption of Canine cancertherapy as a treatment method are propelling market growth. Growing expenditure on animal healthcare in the developed economies due to rising willingness to spend on pet healthcare by owners and initiatives by government for the Canine cancertreatment are the major factors driving the market growth.

Top Driver: Growing demand for ready to eat food will drive the market growth

The increasing number of veterinary clinical studies for evaluating the safety and efficacy of different oncology treatments in pets is further boosting the market growth. AVMA created a database called AVMA Animal Health Studies Database (AAHSD) as a tool for investigators performing prospective veterinary clinical studies. Such studies by the researchers focused on veterinary oncology treatment are anticipated to fuel the market growth over the forecast period. The rising number of these cancer incidents, there is a necessity for effective veterinary oncology treatment in these animals.

Chemotherapy to Make Crucial Contribution for Growth of Global Canine cancer Market

By Therapy ,The chemotherapy segment held the largest market share in terms of revenue in 2019 owing to the increasing number of chemotherapeutic procedures adopted by surgeons due to their several advantages. According to the oncology guidelines by AAHA, chemotherapy is a commonly used veterinary oncology treatment modality in Canine cancermedicine. Moreover, other chemotherapy methods such as conventional, metronomic, and targeted chemotherapy including Tyrosine Kinase Inhibitors are adopted by small animal practitioners. Therefore, the rising adoption of chemotherapy as a treatment modality for cancer in pets is expected to fuel the veterinary oncology market growth.Chemotherapy is followed by radiology treatment due to increasing research studies to test the safety and efficacy of Stereotactic Radiosurgery Treatment in animals. SRT helps control the tumor to an extent and ultimately reduces its toxicity.

The lymphoma cancer type segment accounted for the largest share of revenue in 2019, owing to the increasing number of the pet population, especially canine, being affected by the disease, an estimated incidence rate of 20-100 cases per 100,000 dogs are contracted by this disease. The proven oncology treatment for lymphoma is chemotherapy, which also varies depending on the type of cancer. According to American Kennel Club, the most common types of lymphoma in dogs are mediastinal lymphoma, multicentric lymphoma, alimentary lymphoma, and extranodal lymphoma, which vary in survival rates, aggressiveness, and clinical signs. The organization also states that 80 to 85 % of lymphomas in dogs were found to be multicentric. Lymphoma is followed by mast cell cancer along with mammary and squamous cell cancer. Rising incidence of mast cell cancer in dogs is further expected to drive the market growth.

North America dominate d to witness fastest growth in Global Canine cancer Market

North America is projected to dominate the market over the forecast period. Major factors attributed to the market growth are increasing focus on pet health, the presence of a large number of pet drug manufacturing companies, and speedy adoption of innovative pet care medications. In addition, increasing number of funding for pet oncology treatment in this region by the government and the presence of market giants in the oncology market is also driving the market growth.

The European market is anticipated to be the second largest region in terms of revenue due to the presence of regulatory authorities focused on scientific progress in veterinary and comparative oncology. These authorities collaborate with big market players to focus on developing unparalleled therapeutic solutions for pet oncology.

Players to Focus on Canine cancer Market

Some of the key players in the market are,

• PetCure Oncology;
• Accuray Incorporated;
• Varian Medical Systems;
• Boehringer Ingelheim;
• Elanco;
• Zoetis Karyopharm Therapeutics, Inc.;
• One Health;
• Regeneus Ltd.

National Cancer Institute:  For instance, in July 2019, the National Cancer Institute (NCI) supported clinical trial testing for veterinary oncology treatments in animals. The aim of the trials offered by veterinary medical schools worldwide was to find new cancer treatments that will preserve the dog’s quality of life. The trail was also conducted to provide an insight into how the veterinary oncology treatments and approaches being examined in dogs may be translated to help people with cancer, as the humans and dogs share similar biology for cancer.

Scope of the Report

By Cancer Type

• Lymphoma
• Mast Cell Cancer
• Mammary and Squamous Cell Cancer

By Therapy

• Radiology
• Chemotherapy
• Immunotherapy

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.

2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.

3. It renders definite analysis for changing competitive dynamics.

4. It builds a seven-year estimate based on how the market is predicted to grow.